Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pediatric fever treatment

This article was originally published in The Tan Sheet

Executive Summary

Alternating acetaminophen (12.5 mg/kg) and ibuprofen (5 mg/kg) in young children is more effective for reducing fever than mono-therapy, a randomized, parallel-group trial in the February Archives of Pediatrics & Adolescent Medicine finds. The study was conducted in 464 children aged 6-36 months, with a follow-up period of 10 days. Children who received alternating doses every four hours for three days also received a lower mean number of doses per child in days 1-3, required 22.6% fewer doses from day 1-2 and had fewer fever recurrences on days five and ten, Michael Sarrell, MD, et al., Tel Aviv University, report. Difference in fever reduction between acetaminophen and ibuprofen groups was not statistically significant. Participants "may have been more seriously ill than most of the children who receive over-the-counter antipyretics" since they were recruited at presentation for treatment, the authors note...

You may also be interested in...

Biogen ‘Ready To Launch’ Aducanumab If It Gets The Chance

The company has identified 600 sites of care to treat Alzheimer's patients with aducanumab in the US and is confident on its pricing strategy, management said.

Intuitive Exceeds Expectations In Q1 As Da Vinci Sales And Surgeries Recover

The robotic surgery company recorded $1.29bn in first-quarter revenue, an 18% year-over-year increase. Worldwide da Vinci procedures were up 16% as surgical volumes recovered from the pandemic.

California DTSC Eyes Hair Relaxers, Straighteners For Next Safer Consumer Product Priority

The Department of Toxic Substances Control does not identify specific chemicals of concern in its 2021-2023 Priority Product Draft Work Plan, but says it is focusing on ingredients and endpoints associated with children, women of childbearing age, communities of color and aquatic impacts.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts